• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用复制型4型腺病毒进行口服初免,随后用H5N1亚单位疫苗加强免疫,可促进抗体亲和力成熟并扩大H5N1跨分支中和作用。

Oral priming with replicating adenovirus serotype 4 followed by subunit H5N1 vaccine boost promotes antibody affinity maturation and expands H5N1 cross-clade neutralization.

作者信息

Khurana Surender, Coyle Elizabeth M, Manischewitz Jody, King Lisa R, Ishioka Glenn, Alexander Jeff, Smith Jon, Gurwith Marc, Golding Hana

机构信息

Division of Viral products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, Maryland, United States of America, 20903.

PaxVax, San Diego, CA, United States of America, 92121.

出版信息

PLoS One. 2015 Jan 28;10(1):e0115476. doi: 10.1371/journal.pone.0115476. eCollection 2015.

DOI:10.1371/journal.pone.0115476
PMID:25629161
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4309450/
Abstract

A Phase I trial conducted in 2009-2010 demonstrated that oral vaccination with a replication competent Ad4-H5 (A/Vietnam) vector with dosages ranging from 107-1011 viral particles was well tolerated. HA-specific T-cell responses were efficiently induced, but very limited hemagglutination-inhibiting (HI) humoral responses were measured. However, a single boost of Ad4-H5-Vtn vaccinated individuals with a unadjuvanted licensed H5N1 (A/Vietnam) subunit vaccine resulted in superior HI titers compared with unprimed subjects. In the current study, the impact of Ad4-H5 priming on the quality of the polyclonal humoral immune response was evaluated using a real-time kinetics assay by surface plasmon resonance (SPR). Total binding of serum polyclonal antibodies from the Ad4-H5-Vtn primed groups against both homologous H5N1-A/Vietnam/1194/2004 (clade 1) and heterologous A/Indonesia-5/2005 (clade 2.1) HA1 head domain was significantly higher compared with sera from individuals that received subunit H5N1 vaccination alone. SPR measurements also demonstrated that the antigen-antibody complex dissociation rates (a surrogate for antibody affinity) of serum antibodies against the HA1 of H5N1-A/Vietnam were significantly higher in the Ad4-H5 primed groups compared with those from the unprimed group. Furthermore, strong correlations were observed between the antibody affinities for HA1 (but not HA2) and the virus neutralization titers against the homologous strain and a panel of heterologous clade 2 H5N1 strains. These findings support the concept of oral prime-boost vaccine approaches against pandemic influenza to elicit long-term memory B cells with high affinity capable of rapid response to variant pandemic viruses likely to emerge and adapt to human transmissions.

摘要

2009 - 2010年进行的一项I期试验表明,口服具有复制能力的Ad4 - H5(A/越南)载体,剂量范围为10^7 - 10^11病毒颗粒,耐受性良好。能有效诱导HA特异性T细胞反应,但测得的血凝抑制(HI)体液反应非常有限。然而,用无佐剂的已获许可的H5N1(A/越南)亚单位疫苗对Ad4 - H5 - Vtn接种个体进行单次加强免疫后,与未接种疫苗的受试者相比,HI滴度更高。在本研究中,通过表面等离子体共振(SPR)实时动力学分析评估了Ad4 - H5初免对多克隆体液免疫反应质量的影响。与仅接受H5N1亚单位疫苗接种的个体血清相比,Ad4 - H5 - Vtn初免组血清多克隆抗体对同源H5N1 - A/越南/1194/2004(1系)和异源A/印度尼西亚 - 5/2005(2.1系)HA1头部结构域的总结合力显著更高。SPR测量还表明,与未初免组相比,Ad4 - H5初免组血清抗体针对H5N1 - A/越南HA1的抗原 - 抗体复合物解离速率(抗体亲和力的替代指标)显著更高。此外,观察到针对HA1(而非HA2)的抗体亲和力与针对同源毒株和一组异源2系H5N1毒株的病毒中和滴度之间存在强相关性。这些发现支持了口服初免 - 加强疫苗策略用于大流行性流感的概念,以引发具有高亲和力的长期记忆B细胞,能够对可能出现并适应人际传播的变异大流行性病毒做出快速反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1506/4309450/feb55ba273b5/pone.0115476.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1506/4309450/23b5dab84448/pone.0115476.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1506/4309450/c1939e42cd35/pone.0115476.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1506/4309450/4bc75d7137ad/pone.0115476.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1506/4309450/6ea18dde7671/pone.0115476.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1506/4309450/feb55ba273b5/pone.0115476.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1506/4309450/23b5dab84448/pone.0115476.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1506/4309450/c1939e42cd35/pone.0115476.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1506/4309450/4bc75d7137ad/pone.0115476.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1506/4309450/6ea18dde7671/pone.0115476.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1506/4309450/feb55ba273b5/pone.0115476.g005.jpg

相似文献

1
Oral priming with replicating adenovirus serotype 4 followed by subunit H5N1 vaccine boost promotes antibody affinity maturation and expands H5N1 cross-clade neutralization.用复制型4型腺病毒进行口服初免,随后用H5N1亚单位疫苗加强免疫,可促进抗体亲和力成熟并扩大H5N1跨分支中和作用。
PLoS One. 2015 Jan 28;10(1):e0115476. doi: 10.1371/journal.pone.0115476. eCollection 2015.
2
Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization.用MF59佐剂H5疫苗进行异源初免-加强免疫可促进针对血凝素HA1结构域的抗体亲和力成熟及广泛的H5N1跨分支中和作用。
PLoS One. 2014 Apr 22;9(4):e95496. doi: 10.1371/journal.pone.0095496. eCollection 2014.
3
Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.AS03 佐剂甲型 H5N1 流感疫苗加强免疫可改善异源加强免疫后的免疫应答动力学、幅度和持久性:一项双盲随机对照初级研究的开放性非随机扩展。
Vaccine. 2010 Jan 8;28(3):849-57. doi: 10.1016/j.vaccine.2009.10.017. Epub 2009 Oct 14.
4
Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults.使用AS03A佐剂的异源H5N1疫苗的长期加强免疫方案可在亚洲成年人中诱导快速且广泛的免疫反应。
BMC Infect Dis. 2014 Mar 15;14:142. doi: 10.1186/1471-2334-14-142.
5
Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph Nodes.鼻内接种活流感疫苗可引发纵隔淋巴结中的局部 B 细胞应答。
J Virol. 2018 Apr 13;92(9). doi: 10.1128/JVI.01970-17. Print 2018 May 1.
6
A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity.复制型腺病毒载体流感疫苗可诱导持久的全身和黏膜免疫。
J Clin Invest. 2021 Mar 1;131(5). doi: 10.1172/JCI140794.
7
Monovalent H5 vaccine based on epitope-chimeric HA provides broad cross-clade protection against variant H5N1 viruses in mice.单价 H5 疫苗基于表位嵌合 HA 为小鼠提供针对变异 H5N1 病毒的广泛跨属保护。
Antiviral Res. 2014 May;105:143-51. doi: 10.1016/j.antiviral.2014.03.002. Epub 2014 Mar 15.
8
Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses.针对快速进化的H5亚型病毒开发具有分支特异性和广泛反应性的减毒活流感病毒疫苗。
J Virol. 2017 Jul 12;91(15). doi: 10.1128/JVI.00547-17. Print 2017 Aug 1.
9
Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine.对先前接种过H5N2减毒活流感疫苗的个体进行H5N1灭活流感疫苗免疫反应评估。
Hum Vaccin Immunother. 2015;11(12):2839-48. doi: 10.1080/21645515.2015.1069931.
10
Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming.细胞培养(Vero 细胞)衍生的全病毒无佐剂 H5N1 流感疫苗可诱导持久的交叉反应性记忆免疫应答:两剂或一剂初免后同源或异源加强免疫反应。
Vaccine. 2012 Sep 21;30(43):6127-35. doi: 10.1016/j.vaccine.2012.07.077. Epub 2012 Aug 8.

引用本文的文献

1
Cross-Reactivity Conferred by Homologous and Heterologous Prime-Boost A/H5 Influenza Vaccination Strategies in Humans: A Literature Review.同源和异源初免-加强A/H5流感疫苗接种策略在人类中产生的交叉反应:文献综述
Vaccines (Basel). 2021 Dec 10;9(12):1465. doi: 10.3390/vaccines9121465.
2
Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections.基于腺病毒载体的平台,用于开发有效的疫苗以对抗呼吸道病毒感染。
Clin Transl Immunology. 2021 Oct 12;10(10):e1345. doi: 10.1002/cti2.1345. eCollection 2021.
3
A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity.

本文引用的文献

1
A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response.一种减毒活流感 A(H5N1)疫苗可在无初级抗体应答的情况下诱导长期免疫。
J Infect Dis. 2014 Jun 15;209(12):1860-9. doi: 10.1093/infdis/jiu123. Epub 2014 Mar 5.
2
CD4 T cell help is limiting and selective during the primary B cell response to influenza virus infection.在原发性B细胞对流感病毒感染的应答过程中,CD4 T细胞的辅助作用是有限且具有选择性的。
J Virol. 2014 Jan;88(1):314-24. doi: 10.1128/JVI.02077-13. Epub 2013 Oct 23.
3
Diversity among memory B cells: origin, consequences, and utility.
复制型腺病毒载体流感疫苗可诱导持久的全身和黏膜免疫。
J Clin Invest. 2021 Mar 1;131(5). doi: 10.1172/JCI140794.
4
Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines.用于开发下一代流感疫苗的基于腺病毒载体的疫苗平台。
Vaccines (Basel). 2020 Oct 1;8(4):574. doi: 10.3390/vaccines8040574.
5
Oral Biologic Delivery: Advances Toward Oral Subunit, DNA, and mRNA Vaccines and the Potential for Mass Vaccination During Pandemics.口服生物制剂递呈:口服亚单位疫苗、DNA 疫苗和 mRNA 疫苗的最新进展及其在大流行期间大规模接种的潜力。
Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:517-540. doi: 10.1146/annurev-pharmtox-030320-092348. Epub 2020 Aug 31.
6
High-Capacity Adenoviral Vectors: Expanding the Scope of Gene Therapy.高容量腺相关病毒载体:拓展基因治疗的范围。
Int J Mol Sci. 2020 May 21;21(10):3643. doi: 10.3390/ijms21103643.
7
Seroprevalence of Neutralizing Antibodies to Human Adenovirus Type 4 and 7 in Healthy Populations From Southern China.中国南方健康人群中针对4型和7型人腺病毒的中和抗体血清流行率
Front Microbiol. 2018 Dec 10;9:3040. doi: 10.3389/fmicb.2018.03040. eCollection 2018.
8
A Review of DNA Vaccines Against Influenza.抗流感DNA疫苗综述。
Front Immunol. 2018 Jul 9;9:1568. doi: 10.3389/fimmu.2018.01568. eCollection 2018.
9
Noninvasive vaccination as a casus belli to redeem vaccine value in the face of anti-vaccine movements.面对反疫苗运动,无创接种作为一种开战理由以挽回疫苗的价值。
Integr Mol Med. 2017;4(5). doi: 10.15761/IMM.1000304. Epub 2017 Jul 24.
10
Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses.针对快速进化的H5亚型病毒开发具有分支特异性和广泛反应性的减毒活流感病毒疫苗。
J Virol. 2017 Jul 12;91(15). doi: 10.1128/JVI.00547-17. Print 2017 Aug 1.
记忆 B 细胞的多样性:起源、后果和应用。
Science. 2013 Sep 13;341(6151):1205-11. doi: 10.1126/science.1241146.
4
Human circulating influenza-CD4+ ICOS1+IL-21+ T cells expand after vaccination, exert helper function, and predict antibody responses.人类循环中的流感-CD4+ICOS1+IL-21+T 细胞在接种疫苗后会扩增,发挥辅助功能,并预测抗体反应。
Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):14330-5. doi: 10.1073/pnas.1311998110. Epub 2013 Aug 12.
5
DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults.DNA 引物接种于流感灭活疫苗(H5N1)之前可增加抗体表位谱,并以增强间隔依赖性方式增加成年人中的亲和力成熟。
J Infect Dis. 2013 Aug 1;208(3):413-7. doi: 10.1093/infdis/jit178. Epub 2013 Apr 30.
6
Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study.口服复制型腺病毒血清型 4 载体疫苗预防 H5N1 流感的安全性和免疫原性:一项随机、双盲、安慰剂对照、1 期研究。
Lancet Infect Dis. 2013 Mar;13(3):238-50. doi: 10.1016/S1473-3099(12)70345-6. Epub 2013 Jan 29.
7
AID activity in B cells strongly correlates with polyclonal antibody affinity maturation in-vivo following pandemic 2009-H1N1 vaccination in humans.AID 活动与 2009 年大流行 H1N1 疫苗接种后人体内多克隆抗体亲和力成熟呈强相关性。
PLoS Pathog. 2012 Sep;8(9):e1002920. doi: 10.1371/journal.ppat.1002920. Epub 2012 Sep 13.
8
Oligomeric recombinant H5 HA1 vaccine produced in bacteria protects ferrets from homologous and heterologous wild-type H5N1 influenza challenge and controls viral loads better than subunit H5N1 vaccine by eliciting high-affinity antibodies.细菌表达的寡聚重组 H5 HA1 疫苗可保护雪貂免受同源和异源野生型 H5N1 流感病毒的攻击,通过诱导高亲和力抗体,其控制病毒载量的效果优于亚单位 H5N1 疫苗。
J Virol. 2012 Nov;86(22):12283-93. doi: 10.1128/JVI.01596-12. Epub 2012 Sep 5.
9
Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion.AS03 的研制与评价:一种含 α-生育酚和角鲨烯的油包水乳剂佐剂系统。
Expert Rev Vaccines. 2012 Mar;11(3):349-66. doi: 10.1586/erv.11.192.
10
Immune response following H1N1pdm09 vaccination: differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender.H1N1pdm09 疫苗接种后的免疫反应:按年龄和性别分层的年轻成年人和老年人群中抗体库和亲和力的差异。
J Infect Dis. 2012 Feb 15;205(4):610-20. doi: 10.1093/infdis/jir791. Epub 2011 Dec 29.